IL6 and cryptococcosis: Tocilizumab, an interleukin-6 (IL-6) receptor antagonist, demonstrated the strongest association with fungal pneumonia, specifically COVID-19-associated pulmonary aspergillosis (CAPA) and cryptococcosis (29, 30).